Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - The go-easy study

Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B. J. M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef, Irene E. van der Horst-Bruinsma

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective. Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS). Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS. To date, the effect of GOL on the incidence of AAU in AS is unknown. The objective was to study the AAU occurrence rate in patients with AS during GOL treatment and secondarily, the efficacy of GOL in daily clinical practice. Methods. The study was a multicenter prospective study in a real-world setting in patients with AS who were treated with GOL for 12 months. The occurrence of AAU was assessed in the year before the initial TNFi treatment and during GOL treatment and calculated for the period at risk for a new AAU. Measures for disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)] and treatment response [Assessment of Spondyloarthritis international Society (ASAS20 score)] were collected. Results. In total, 93 patients (65% male, 55% TNFi-naive, 27% history of AAU) were included, with a median disease duration of 7 years and ASDAS score of 3.1. During GOL treatment, the AAU occurrence rate was reduced from 11.1 to 2.2 per 100 patient-years (rate-ratio 0.20, 95% CI 0.04-0.91). After 3 months of treatment, 41% of the patients experienced a clinically important improvement of the ASDAS score (p < 0.001) and 36% an ASDAS20 response (p < 0.001). At month 12, 49% had achieved an ASAS20 response (p < 0.001). Conclusion. In AS, the AAU occurrence rate and disease activity decreased significantly during GOL treatment. Therefore, GOL can be considered a good choice in patients with AS who need a TNFi, especially in cases of recurrent AAU. (EudraCT number: 2012-002458-21)
Original languageEnglish
Pages (from-to)153-159
JournalJournal of Rheumatology
Volume46
Issue number2
DOIs
Publication statusPublished - 2019

Cite this

van Bentum, Rianne E. ; Heslinga, Sjoerd C. ; Nurmohamed, Michael T. ; Gerards, Andreas H. ; Griep, Ed N. ; Koehorst, Charlotte B. J. M. ; Kok, Marc R. ; Schilder, Anna M. ; Verhoef, Marijn ; van der Horst-Bruinsma, Irene E. / Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - The go-easy study. In: Journal of Rheumatology. 2019 ; Vol. 46, No. 2. pp. 153-159.
@article{638e2e1f78e144cba51b43844d55e495,
title = "Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - The go-easy study",
abstract = "Objective. Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS). Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS. To date, the effect of GOL on the incidence of AAU in AS is unknown. The objective was to study the AAU occurrence rate in patients with AS during GOL treatment and secondarily, the efficacy of GOL in daily clinical practice. Methods. The study was a multicenter prospective study in a real-world setting in patients with AS who were treated with GOL for 12 months. The occurrence of AAU was assessed in the year before the initial TNFi treatment and during GOL treatment and calculated for the period at risk for a new AAU. Measures for disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)] and treatment response [Assessment of Spondyloarthritis international Society (ASAS20 score)] were collected. Results. In total, 93 patients (65{\%} male, 55{\%} TNFi-naive, 27{\%} history of AAU) were included, with a median disease duration of 7 years and ASDAS score of 3.1. During GOL treatment, the AAU occurrence rate was reduced from 11.1 to 2.2 per 100 patient-years (rate-ratio 0.20, 95{\%} CI 0.04-0.91). After 3 months of treatment, 41{\%} of the patients experienced a clinically important improvement of the ASDAS score (p < 0.001) and 36{\%} an ASDAS20 response (p < 0.001). At month 12, 49{\%} had achieved an ASAS20 response (p < 0.001). Conclusion. In AS, the AAU occurrence rate and disease activity decreased significantly during GOL treatment. Therefore, GOL can be considered a good choice in patients with AS who need a TNFi, especially in cases of recurrent AAU. (EudraCT number: 2012-002458-21)",
author = "{van Bentum}, {Rianne E.} and Heslinga, {Sjoerd C.} and Nurmohamed, {Michael T.} and Gerards, {Andreas H.} and Griep, {Ed N.} and Koehorst, {Charlotte B. J. M.} and Kok, {Marc R.} and Schilder, {Anna M.} and Marijn Verhoef and {van der Horst-Bruinsma}, {Irene E.}",
year = "2019",
doi = "10.3899/jrheum.180312",
language = "English",
volume = "46",
pages = "153--159",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - The go-easy study. / van Bentum, Rianne E.; Heslinga, Sjoerd C.; Nurmohamed, Michael T.; Gerards, Andreas H.; Griep, Ed N.; Koehorst, Charlotte B. J. M.; Kok, Marc R.; Schilder, Anna M.; Verhoef, Marijn; van der Horst-Bruinsma, Irene E.

In: Journal of Rheumatology, Vol. 46, No. 2, 2019, p. 153-159.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - The go-easy study

AU - van Bentum, Rianne E.

AU - Heslinga, Sjoerd C.

AU - Nurmohamed, Michael T.

AU - Gerards, Andreas H.

AU - Griep, Ed N.

AU - Koehorst, Charlotte B. J. M.

AU - Kok, Marc R.

AU - Schilder, Anna M.

AU - Verhoef, Marijn

AU - van der Horst-Bruinsma, Irene E.

PY - 2019

Y1 - 2019

N2 - Objective. Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS). Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS. To date, the effect of GOL on the incidence of AAU in AS is unknown. The objective was to study the AAU occurrence rate in patients with AS during GOL treatment and secondarily, the efficacy of GOL in daily clinical practice. Methods. The study was a multicenter prospective study in a real-world setting in patients with AS who were treated with GOL for 12 months. The occurrence of AAU was assessed in the year before the initial TNFi treatment and during GOL treatment and calculated for the period at risk for a new AAU. Measures for disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)] and treatment response [Assessment of Spondyloarthritis international Society (ASAS20 score)] were collected. Results. In total, 93 patients (65% male, 55% TNFi-naive, 27% history of AAU) were included, with a median disease duration of 7 years and ASDAS score of 3.1. During GOL treatment, the AAU occurrence rate was reduced from 11.1 to 2.2 per 100 patient-years (rate-ratio 0.20, 95% CI 0.04-0.91). After 3 months of treatment, 41% of the patients experienced a clinically important improvement of the ASDAS score (p < 0.001) and 36% an ASDAS20 response (p < 0.001). At month 12, 49% had achieved an ASAS20 response (p < 0.001). Conclusion. In AS, the AAU occurrence rate and disease activity decreased significantly during GOL treatment. Therefore, GOL can be considered a good choice in patients with AS who need a TNFi, especially in cases of recurrent AAU. (EudraCT number: 2012-002458-21)

AB - Objective. Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS). Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS. To date, the effect of GOL on the incidence of AAU in AS is unknown. The objective was to study the AAU occurrence rate in patients with AS during GOL treatment and secondarily, the efficacy of GOL in daily clinical practice. Methods. The study was a multicenter prospective study in a real-world setting in patients with AS who were treated with GOL for 12 months. The occurrence of AAU was assessed in the year before the initial TNFi treatment and during GOL treatment and calculated for the period at risk for a new AAU. Measures for disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)] and treatment response [Assessment of Spondyloarthritis international Society (ASAS20 score)] were collected. Results. In total, 93 patients (65% male, 55% TNFi-naive, 27% history of AAU) were included, with a median disease duration of 7 years and ASDAS score of 3.1. During GOL treatment, the AAU occurrence rate was reduced from 11.1 to 2.2 per 100 patient-years (rate-ratio 0.20, 95% CI 0.04-0.91). After 3 months of treatment, 41% of the patients experienced a clinically important improvement of the ASDAS score (p < 0.001) and 36% an ASDAS20 response (p < 0.001). At month 12, 49% had achieved an ASAS20 response (p < 0.001). Conclusion. In AS, the AAU occurrence rate and disease activity decreased significantly during GOL treatment. Therefore, GOL can be considered a good choice in patients with AS who need a TNFi, especially in cases of recurrent AAU. (EudraCT number: 2012-002458-21)

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060944470&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30385705

U2 - 10.3899/jrheum.180312

DO - 10.3899/jrheum.180312

M3 - Article

VL - 46

SP - 153

EP - 159

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -